BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 14, Issue 35
This Article
Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
  • Total Article Views (10752)
All Articles published online
The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-2) series.
Item 
Count 
PDF543
HTML9312
Figures (1-3)655
Tables (1-2)242
 Sum=10752
Sep 21, 2008 (publication date) through Nov 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Cited by in CrossRef
For: Gisbert JP. “Rescue” regimens after Helicobacter pylori treatment failure. World J Gastroenterol 2008; 14(35): 5385-5402 [PMID: 18803350 DOI: 10.3748/wjg.14.5385]
URL: https://www.wjgnet.com/1007-9327/full/v14/i35/5385.htm
Number Citing Articles
1
Philip C. Andrews, Richard L. Ferrero, Peter C. Junk, Ish Kumar, Quynh Luu, Kim Nguyen, James W. Taylor. Bismuth(iii) complexes derived from non-steroidal anti-inflammatory drugs and their activity against Helicobacter pylori. Dalton Transactions 2010; 39(11): 2861 doi: 10.1039/c000164c
2
Neil S. Seligman, Wingkan Sbar, Vincenzo Berghella. Pouch function and gastrointestinal complications during pregnancy after ileal pouch-anal anastomosis. The Journal of Maternal-Fetal & Neonatal Medicine 2011; 24(3): 525 doi: 10.3109/14767058.2010.494745
3
Nuno Almeida, Maria Manuel Donato, José Manuel Romãozinho, Cristina Luxo, Olga Cardoso, Maria Augusta Cipriano, Carol Marinho, Alexandra Fernandes, Carlos Calhau, Carlos Sofia. Beyond Maastricht IV: are standard empiric triple therapies for Helicobacter pylori still useful in a South-European country?. BMC Gastroenterology 2015; 15(1) doi: 10.1186/s12876-015-0245-y
4
Alicia C. Marin, Olga P. Nyssen, Adrian G. McNicholl, Javier P. Gisbert. Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis. Drugs 2017; 77(7): 765 doi: 10.1007/s40265-017-0730-4
5
Mei-Jyh Chen, Po-Yueh Chen, Yu-Jen Fang, Ming-Jong Bair, Chieh-Chang Chen, Chien-Chuan Chen, Tsung-Hua Yang, Ji-Yuh Lee, Chien-Chun Yu, Chia-Chi Kuo, Min-Chin Chiu, Chu-Kuang Chou, Chi-Yi Chen, Wen-Hao Hu, Min-Horn Tsai, Yao-Chun Hsu, Chia-Tung Shun, Jiing-Chyuan Luo, Jaw-Town Lin, Emad M El-Omar, Ming-Shiang Wu, Jyh-Ming Liou. Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: two multicentre, open-label, randomised controlled, non-inferiority trials. The Lancet Gastroenterology & Hepatology 2023; 8(7): 623 doi: 10.1016/S2468-1253(23)00097-3
6
Morris O. Makobongo, Leo Einck, Richard M. Peek, D. Scott Merrell, Asad U Khan. In Vitro Characterization of the Anti-Bacterial Activity of SQ109 against Helicobacter pylori. PLoS ONE 2013; 8(7): e68917 doi: 10.1371/journal.pone.0068917
7
Valerie Josephine Dirjayanto, Jessica Audrey, Daniel Martin Simadibrata. Vonoprazan-amoxicillin dual regimen with <i>Saccharomyces boulardii</i> as a rescue therapy for <i>Helicobacter pylori</i>: Current perspectives and implications. World Journal of Gastroenterology 2024; 30(10): 1280-1286 doi: 10.3748/wjg.v30.i10.1280
8
Javier P. Gisbert, Xavier Calvet, Juan Ferrándiz, Juan Mascort, Pablo Alonso-Coello, Mercè Marzo. Guía de práctica clínica sobre el manejo del paciente con dispepsia. Actualización 2012. Atención Primaria 2012; 44(12): 727.e1 doi: 10.1016/j.aprim.2012.05.003
9
Helicobacter pylori Oncogenicity: Mechanism, Prevention, and Risk Factors. The Scientific World Journal 2020; 2020: 1 doi: 10.1155/2020/3018326
10
Yinling Xu, Feichi Chen, Heli Wen. Global incidence and prevalence of gastritis and duodenitis from 1990 to 2019: A systematic analysis for the Global Burden of Disease Study 2019. Journal of Gastroenterology and Hepatology 2024; 39(8): 1563 doi: 10.1111/jgh.16572
11
A. Cuadrado-Lavin, J. R. Salcines-Caviedes, M. F. Carrascosa, P. Mellado, I. Monteagudo, J. Llorca, M. Cobo, M. R. Campos, B. Ayestaran, A. Fernandez-Pousa, E. Gonzalez-Colominas. Antimicrobial susceptibility of Helicobacter pylori to six antibiotics currently used in Spain. Journal of Antimicrobial Chemotherapy 2012; 67(1): 170 doi: 10.1093/jac/dkr410
12
Javier P. Gisbert, Adrian G. McNicholl. Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies. Helicobacter 2017; 22(4) doi: 10.1111/hel.12392
13
Javier P. Gisbert. Review: Second-line rescue therapy of Helicobacter pylori infection. Therapeutic Advances in Gastroenterology 2009; 2(6): 331 doi: 10.1177/1756283X09347109
14
Yuqin Li, Xiayue Huang, Linhua Yao, Ruihua Shi, Guoxin Zhang. Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis. Wiener klinische Wochenschrift 2010; 122(13-14): 413 doi: 10.1007/s00508-010-1404-3
15
Philip C. Andrews, Richard L. Ferrero, Peter C. Junk, Roshani M. Peiris. A sweeter way to combat Helicobacter pylori? Bismuth(III) complexes and oxido-clusters derived from non-nutritive sweeteners and their activity against H. pylori. Journal of Organometallic Chemistry 2013; 724: 88 doi: 10.1016/j.jorganchem.2012.10.024
16
J. P. Gisbert. Letter: third‐line rescue therapy with levofloxacin after failure of two treatments to eradicate Helicobacter pylori infection. Alimentary Pharmacology & Therapeutics 2012; 35(12): 1484 doi: 10.1111/j.1365-2036.2012.05117.x
17
Javier P. Gisbert, Jesús Barrio, Inés Modolell, Javier Molina-Infante, Angeles Perez Aisa, Manuel Castro-Fernández, Luis Rodrigo, Angel Cosme, Jose Luis Gisbert, Miguel Fernández-Bermejo, Santiago Marcos, Alicia C. Marín, Adrián G. McNicholl. Helicobacter Pylori First-Line and Rescue Treatments in the Presence of Penicillin Allergy. Digestive Diseases and Sciences 2015; 60(2): 458 doi: 10.1007/s10620-014-3365-2
18
Wen Gao, Hong Cheng, Fulian Hu, Jiang Li, Lihui Wang, Guibin Yang, Le Xu, Xiaoli Zheng. The Evolution of Helicobacter pylori Antibiotics Resistance Over 10 Years in Beijing, China. Helicobacter 2010; 15(5): 460 doi: 10.1111/j.1523-5378.2010.00788.x
19
Te-Fu Lin, Ping-I Hsu. Second-line rescue treatment of <i>Helicobacter pylori</i> infection: Where are we now?. World Journal of Gastroenterology 2018; 24(40): 4548-4553 doi: 10.3748/wjg.v24.i40.4548
20
Zhi Qiang Song, Li Ya Zhou. Esomeprazole, minocycline, metronidazole and bismuth as first‐line and second‐line regimens for Helicobacter pylori eradication. Journal of Digestive Diseases 2016; 17(4): 260 doi: 10.1111/1751-2980.12334
21
Carmen Cofré. Helicobacter pylori: una puesta al día en pediatría. Medwave 2011; 11(07) doi: 10.5867/medwave.2011.07.5056
22
Wei-Chen Tai, Chien-Hua Chiu, Chih-Ming Liang, Kuo-Chin Chang, Chung-Mou Kuo, Yi-Chun Chiu, Keng-Liang Wu, Ming-Luen Hu, Yeh-Pin Chou, Shue-Shian Chiou, King-Wah Chiu, Chung-Huang Kuo, Tsung-Hui Hu, Ming-Tsung Lin, Seng-Kee Chuah. Ten-Day versus 14-Day Levofloxacin-Containing Triple Therapy for Second-Line Anti-Helicobacter pyloriEradication in Taiwan. Gastroenterology Research and Practice 2013; 2013: 1 doi: 10.1155/2013/932478
23
Deng-Chyang Wu, Ping-I Hsu, Hui-Hwa Tseng, Feng-Woei Tsay, Kwok-Hung Lai, Chao-Hung Kuo, Sheng-Wen Wang, Angela Chen. Helicobacter pylori Infection. Medicine 2011; 90(3): 180 doi: 10.1097/MD.0b013e31821c9d1c
24
Erik C. von Rosenvinge, Graeme A. O'May, Sandra Macfarlane, George T. Macfarlane, Mark E. Shirtliff. Microbial biofilms and gastrointestinal diseases. Pathogens and Disease 2013; 67(1): 25 doi: 10.1111/2049-632X.12020
25
Jun-Won Chung, Jeong Hoon Lee, Hwoon-Yong Jung, Sung-Cheol Yun, Tae-Hoon Oh, Kee Don Choi, Ho June Song, Gin Hyug Lee, Jin-Ho Kim. Second-line Helicobacter pylori Eradication: A Randomized Comparison of 1-week or 2-week Bismuth-containing Quadruple Therapy. Helicobacter 2011; 16(4): 289 doi: 10.1111/j.1523-5378.2011.00844.x
26
F. Sierra, J. D. Forero, M. Rey, M. L. Botero, A. Cárdenas. Pilot study: miscellaneous therapy is highly successful for Helicobacter pylori eradication. Alimentary Pharmacology & Therapeutics 2013; 37(12): 1165 doi: 10.1111/apt.12329
27
Miguel García-Ferrús, Ana González, María Consuelo Pina-Pérez, Maria Antonia Ferrús. Helicobacter pylori Is Present at Quantifiable Levels in Raw Vegetables in the Mediterranean Area of Spain. Agriculture 2022; 12(3): 339 doi: 10.3390/agriculture12030339
28
Krisztina Hagymási, Zsolt Tulassay. Peptic ulcer: facts and questions – 2010. Orvosi Hetilap 2010; 151(26): 1054 doi: 10.1556/oh.2010.28892
29
Hyuk Yoon, Nayoung Kim, Byoung Hwan Lee, Tae Jun Hwang, Dong Ho Lee, Young Soo Park, Ryoung Hee Nam, Hyun Chae Jung, In Sung Song. Moxifloxacin‐Containing Triple Therapy as Second‐Line Treatment for Helicobacter pylori Infection: Effect of Treatment Duration and Antibiotic Resistance on the Eradication Rate. Helicobacter 2009; 14(5): 429 doi: 10.1111/j.1523-5378.2009.00709.x
30
P Malfertheiner, F Megraud, C A O'Morain, J P Gisbert, E J Kuipers, A T Axon, F Bazzoli, A Gasbarrini, J Atherton, D Y Graham, R Hunt, P Moayyedi, T Rokkas, M Rugge, M Selgrad, S Suerbaum, K Sugano, E M El-Omar. Management ofHelicobacter pyloriinfection—the Maastricht V/Florence Consensus Report. Gut 2017; 66(1): 6 doi: 10.1136/gutjnl-2016-312288
31
Tzung‐Shiun Wu, Huang‐Ming Hu, Fu‐Chen Kuo, Chao‐Hung Kuo. Eradication of Helicobacter pylori infection. The Kaohsiung Journal of Medical Sciences 2014; 30(4): 167 doi: 10.1016/j.kjms.2013.11.003
32
Ryan P. Mynatt, George A. Davis, Frank Romanelli. Peptic Ulcer Disease: Clinically Relevant Causes and Treatments. Orthopedics 2009; 32(2): 104 doi: 10.3928/01477447-20090201-25
33
Javier P. Gisbert. Rifabutin for the Treatment of Helicobacter pylori Infection: A Review. Pathogens 2020; 10(1): 15 doi: 10.3390/pathogens10010015
34
Javier P. Gisbert, Ángeles Pérez-Aisa, Fernando Bermejo, Manuel Castro-Fernández, Pedro Almela, Jesús Barrio, Ángel Cosme, Inés Modolell, Felipe Bory, Miguel Fernández-Bermejo, Luis Rodrigo, Jesús Ortuño, Pilar Sánchez-Pobre, Sam Khorrami, Alejandro Franco, Albert Tomas, Iván Guerra, Eloisa Lamas, Julio Ponce, Xavier Calvet. Second-line Therapy With Levofloxacin After Failure of Treatment to Eradicate Helicobacter pylori Infection. Journal of Clinical Gastroenterology 2013; 47(2): 130 doi: 10.1097/MCG.0b013e318254ebdd
35
Soichiro Sue, Nobumi Suzuki, Wataru Shibata, Tomohiko Sasaki, Hiroaki Yamada, Hiroaki Kaneko, Toshihide Tamura, Tomohiro Ishii, Masaaki Kondo, Shin Maeda. First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin. Gastroenterology Research and Practice 2017; 2017: 1 doi: 10.1155/2017/2019802
36
Amin Talebi Bezmin Abadi. Therapy ofHelicobacter pylori: Present Medley and Future Prospective. BioMed Research International 2014; 2014: 1 doi: 10.1155/2014/124607
37
Hidekazu Suzuki, Hideki Mori. World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat. Journal of Gastroenterology 2018; 53(3): 354 doi: 10.1007/s00535-017-1407-1
38
Xiaojun He, Xiangwen Liao, Hongyan Li, Wei Xia, Hongzhe Sun. Bismuth-Induced Inactivation of Ferric Uptake Regulator from Helicobacter pylori. Inorganic Chemistry 2017; 56(24): 15041 doi: 10.1021/acs.inorgchem.7b02380
39
Olga P. Nyssen, Ángeles Pérez‐Aisa, Bojan Tepes, Luis Rodrigo‐Sáez, Pilar M. Romero, Alfredo Lucendo, Manuel Castro‐Fernández, Perminder Phull, Jesús Barrio, Luis Bujanda, Juan Ortuño, Miguel Areia, Natasa Brglez Jurecic, José María Huguet, Noelia Alcaide, Irina Voynovan, José María Botargues Bote, Inés Modolell, Jorge Pérez Lasala, Inés Ariño, Laimas Jonaitis, Manuel Dominguez‐Cajal, György Buzas, Frode Lerang, Monica Perona, Dmitry Bordin, Toni Axon, Antonio Gasbarrini, Ricardo Marcos Pinto, Yaron Niv, Limas Kupcinskas, Ante Tonkic, Marcis Leja, Theodore Rokkas, Lyudmila Boyanova, Oleg Shvets, Marino Venerito, Peter Bytzer, Adrian Goldis, Ilkay Simsek, Vincent Lamy, Krzysztof Przytulski, Lumír Kunovský, Lisette Capelle, Tomica Milosavljevic, María Caldas, Ana Garre, Francis Mégraud, Colm O'Morain, Javier P. Gisbert. Helicobacter pylorifirst‐line and rescue treatments in patients allergic to penicillin: Experience from the European Registry onH pylorimanagement (Hp‐EuReg). Helicobacter 2020; 25(3) doi: 10.1111/hel.12686
40
Javier P. Gisbert, Marco Romano, Javier Molina-Infante, Alfredo J. Lucendo, Enrique Medina, Inés Modolell, Manuel Rodríguez-Tellez, Blas Gomez, Jesús Barrio, Monica Perona, Juan Ortuño, Inés Ariño, Juan Enrique Domínguez-Muñoz, Ángeles Perez-Aisa, Fernando Bermejo, Jose Luis Domínguez, Pedro Almela, Judith Gomez-Camarero, Judith Millastre, Elisa Martin-Noguerol, Antonietta G. Gravina, Marco Martorano, Agnese Miranda, Alessandro Federico, Miguel Fernandez-Bermejo, Teresa Angueira, Luis Ferrer-Barcelo, Nuria Fernández, Alicia C. Marín, Adrián G. McNicholl. Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments. Digestive and Liver Disease 2015; 47(2): 108 doi: 10.1016/j.dld.2014.10.009
41
Eskandar Hajiani, Pezhman Alavinejad, Nahid Avandi, Abdol Rahim Masjedizadeh, Ali Akbar Shayesteh. Comparison of Levofloxacin-Based, 10-day Sequential Therapy with 14-day Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial. Middle East Journal of Digestive Diseases 2018; 10(4): 242 doi: 10.15171/mejdd.2018.117
42
J. P. Gisbert, M. Romano, A. G. Gravina, P. Solís‐Muñoz, F. Bermejo, J. Molina‐Infante, M. Castro‐Fernández, J. Ortuño, A. J. Lucendo, M. Herranz, I. Modolell, F. del Castillo, J. Gómez, J. Barrio, B. Velayos, B. Gómez, J. L. Domínguez, A. Miranda, M. Martorano, A. Algaba, M. Pabón, T. Angueira, L. Fernández‐Salazar, A. Federico, A. C. Marín, A. G. McNicholl. Helicobacter pylori second‐line rescue therapy with levofloxacin‐ and bismuth‐containing quadruple therapy, after failure of standard triple or non‐bismuth quadruple treatments. Alimentary Pharmacology & Therapeutics 2015; 41(8): 768 doi: 10.1111/apt.13128
43
Javier P. Gisbert. Optimization Strategies Aimed to Increase the Efficacy of Helicobacter pylori Eradication Therapies with Quinolones. Molecules 2020; 25(21): 5084 doi: 10.3390/molecules25215084
44
Brunella Posteraro, Patrizia Posteraro, Maurizio Sanguinetti. Molecular Medical Microbiology. 2015; : 1237 doi: 10.1016/B978-0-12-397169-2.00068-8
45
Soichiro Sue, Tomohiko Sasaki, Hiroaki Kaneko, Kuniyasu Irie, Masaaki Kondo, Shin Maeda. Helicobacter pylori rescue treatment with vonoprazan, metronidazole, and sitafloxacin in the presence of penicillin allergy. JGH Open 2021; 5(2): 307 doi: 10.1002/jgh3.12492
46
Antonio Francesco Ciccaglione, Mara Di Giulio, Silvia Di Lodovico, Emanuela Di Campli, Luigina Cellini, Leonardo Marzio. Bovine lactoferrin enhances the efficacy of levofloxacin-based triple therapy as first-line treatment ofHelicobacter pyloriinfection: anin vitroandin vivostudy. Journal of Antimicrobial Chemotherapy 2019; 74(4): 1069 doi: 10.1093/jac/dky510
47
Javier P. Gisbert. Tratamientos de rescate ante el fracaso erradicador de Helicobacter pylori. Gastroenterología y Hepatología 2011; 34(2): 89 doi: 10.1016/j.gastrohep.2010.10.013
48
Davide Roccarina, Francesco Franceschi, Maria Assunta Zocco, Matteo Garcovich, Giovanni Gasbarrini, Antonio Gasbarrini. Different Antibiotic No Culture Eradicating (DANCE) strategy: An easy way to manage H. pylori eradication. Digestive and Liver Disease 2012; 44(11): 889 doi: 10.1016/j.dld.2012.05.010
49
Bilal Ergül, Zeynal Doğan,, Murat Sarikaya, Levent Filik. The Efficacy of Two‐Week Quadruple First‐Line Therapy with Bismuth, Lansoprazole, Amoxicillin, Clarithromycin on Helicobacter pylori Eradication: A Prospective Study. Helicobacter 2013; 18(6): 454 doi: 10.1111/hel.12086
50
J. MOLINA‐INFANTE, B. PEREZ‐GALLARDO, M. FERNANDEZ‐BERMEJO, M. HERNANDEZ‐ALONSO, G. VINAGRE, C. DUEÑAS, J. M. MATEOS‐RODRIGUEZ, G. GONZALEZ‐GARCIA, E. G. ABADIA, J. P. GISBERT. Clinical trial: clarithromycin vs. levofloxacin in first‐line triple and sequential regimens for Helicobacter pylori eradication. Alimentary Pharmacology & Therapeutics 2010; 31(10): 1077 doi: 10.1111/j.1365-2036.2010.04274.x
51
Yakhya Dieye, Cheikh Momar Nguer, Fatou Thiam, Abou Abdallah Malick Diouara, Cheikh Fall. Recombinant Helicobacter pylori Vaccine Delivery Vehicle: A Promising Tool to Treat Infections and Combat Antimicrobial Resistance. Antibiotics 2022; 11(12): 1701 doi: 10.3390/antibiotics11121701
52
Metin Küçükazman, Ayse Kefeli, Sebahat Basyigit, Abdullah Özgür Yeniova, Yasar Nazligül, Ibrahim Halil Akkus, Ayla Tezer, Servet Guresci. Efficacy of Bismuth-Containing Quadruple Therapy as First-line Treatment for Helicobacter pylori Infection. Euroasian Journal of Hepato-Gastroenterology 2012; 2(2): 90 doi: 10.5005/jp-journals-10018-1041
53
Zhiqiang Song, Baojun Suo, Lingyun Zhang, Liya Zhou. Rabeprazole, Minocycline, Amoxicillin, and Bismuth as First‐Line and Second‐Line Regimens for Helicobacter pylori Eradication. Helicobacter 2016; 21(6): 462 doi: 10.1111/hel.12313
54
Amin Talebi Bezmin Abadi. A Rare Case of Helicobacter pylori Mix Infections and Recurrence of Duodenal Ulcers. MOJ Clinical & Medical Case Reports 2014; 1(1) doi: 10.15406/mojcr.2014.01.00001
55
Yongming Liu, Chen Shen, Xihui Zhang, Huan Yu, Fujun Wang, Yangyun Wang, Leshuai W Zhang. Exposure and nephrotoxicity concern of bismuth with the occurrence of autophagy. Toxicology and Industrial Health 2018; 34(3): 188 doi: 10.1177/0748233717746810
56
Antonio Francesco Ciccaglione, Luigina Cellini, Laurino Grossi, Lamberto Manzoli, Leonardo Marzio. A Triple and Quadruple Therapy with Doxycycline and Bismuth for First‐Line Treatment of Helicobacter pylori Infection: A Pilot Study. Helicobacter 2015; 20(5): 390 doi: 10.1111/hel.12209
57
Hazel Mitchell, Peter Katelaris. Epidemiology, clinical impacts and current clinical management of Helicobacter pylori infection. Medical Journal of Australia 2016; 204(10): 376 doi: 10.5694/mja16.00104
58
Stefan Hagel, Tony Bruns, Marcus Kantowski, Peter Fix, Thomas Seidel, Andreas Stallmach. Cholestatic hepatitis, acute acalculous cholecystitis, and hemolytic anemia: primary Epstein–Barr virus infection under azathioprine. Inflammatory Bowel Diseases 2009; 15(11): 1613 doi: 10.1002/ibd.20856
59
Marco Berning, Susanne Krasz, Joachim Labenz, Stephan Miehlke. Moderne Helicobacter-pylori-Therapien in Zeiten zunehmender Antibiotikaresistenz. Medizinische Klinik 2010; 105(11): 787 doi: 10.1007/s00063-010-1135-2
60
Diego Burgos‐Santamaría, Adrian G. McNicholl, Javier P. Gisbert. Empirical Helicobacter pylori rescue therapy: an 18‐year single‐centre study of 1200 patients . GastroHep 2019; 1(6): 311 doi: 10.1002/ygh2.372
61
Jay Luther, William D. Chey, Richard J. Saad. A Clinician's Guide to Salvage Therapy for PersistentHelicobacter pyloriInfection. Hospital Practice 2011; 39(1): 133 doi: 10.3810/hp.2011.02.383
62
J.-M. Liou, C.-C. Chen, C.-Y. Chang, M.-J. Chen, Y.-J. Fang, J.-Y. Lee, C.-C. Chen, S.-J. Hsu, Y.-C. Hsu, C.-H. Tseng, P.-H. Tseng, L. Chang, W.-H. Chang, H.-P. Wang, C.-T. Shun, J.-Y. Wu, Y.-C. Lee, J.-T. Lin, M.-S. Wu. Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial. Journal of Antimicrobial Chemotherapy 2013; 68(2): 450 doi: 10.1093/jac/dks407
63
Jyh-Ming Liou, Po-Yueh Chen, Jiing-Chyuan Luo, Ji-Yuh Lee, Chieh-Chang Chen, Yu-Jen Fang, Tsung-Hua Yang, Chi-Yang Chang, Ming-Jong Bair, Mei-Jyh Chen, Yao-Chun Hsu, Wen-Feng Hsu, Chun-Chao Chang, Jaw-Town Lin, Chia-Tung Shun, Emad M. El-Omar, Ming-Shiang Wu, Jyh-Ming Liou, Yi-Chia Lee, Jaw-Town Lin, Chun-Ying Wu, Jeng-Yih Wu, Ching-Chow Chen, Chun-Hung Lin, Yu-Ren Fang, Ming-Jong Bair, Jiing-Chyuan Luo, Ming-Shiang Wu, Tsu-Yao Cheng, Ping-Huei Tseng, Han-Mo Chiu, Chun-Chao Chang, Chien-Chun Yu, Min-Chin Chiu, Yen-Nien Chen, Wen-Hao Hu, Chu-Kuang Chou, Chi-Ming Tai, Ching-Tai Lee, Wen-Lun Wang, Wen-Shiung Chang. Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection. Gastroenterology 2018; 155(4): 1109 doi: 10.1053/j.gastro.2018.06.047
64
Jonathan Efron. Post‐Surgical Recurrence of Ileal Crohn’s Disease. World Journal of Surgery 2010; 34(7): 1627 doi: 10.1007/s00268-010-0498-0
65
Sarah Gurney, Laura Carvalho, Carrie Gonzalez, Esperanza Galaviz, Frances Sonstein. An Efficacious and Cost-Effective Pharmacologic Treatment for Helicobacter pylori. The Journal for Nurse Practitioners 2014; 10(1): 22 doi: 10.1016/j.nurpra.2013.09.013
66
Jaime Natan Eisig, Fernando Marcuz Silva, Ricardo Correa Barbuti, Tomás Navarro-Rodriguez, Joaquim Prado P Moraes-Filho, José Pedrazzoli Jr. Helicobacter pylori antibiotic resistance in Brazil: clarithromycin is still a good option. Arquivos de Gastroenterologia 2011; 48(4): 261 doi: 10.1590/S0004-28032011000400008
67
Javier P. Gisbert. Rescue Therapy forHelicobacter pyloriInfection 2012. Gastroenterology Research and Practice 2012; 2012: 1 doi: 10.1155/2012/974594
68
Sohaib Khan, Mohamed Sharaf, Ishfaq Ahmed, Tehsin Ullah Khan, Samah Shabana, Muhammad Arif, Syed Shabi Ul Hassan Kazmi, Chenguang Liu. Potential utility of nano-based treatment approaches to address the risk ofHelicobacter pylori. Expert Review of Anti-infective Therapy 2022; 20(3): 407 doi: 10.1080/14787210.2022.1990041
69
Li-Yang Gu, Wei-Wei Lin, Hong Lu, Xiao-Yu Chen, Zhi-Zheng Ge, Xiao-Bo Li. Quadruple Therapy with Medications Containing Either Rufloxacin or Furazolidone as a Rescue regimen in the Treatment of Helicobacter pylori-Infected Dyspepsia Patients: A Randomized Pilot Study. Helicobacter 2011; 16(4): 284 doi: 10.1111/j.1523-5378.2011.00848.x
70
Javier P. Gisbert, Xavier Calvet, Juan Ferrándiz, Juan Mascort, Pablo Alonso-Coello, Mercè Marzo. Guía de práctica clínica sobre el manejo del paciente con dispepsia. Actualización 2012. Gastroenterología y Hepatología 2012; 35(10): 725.e1 doi: 10.1016/j.gastrohep.2012.05.002
71
Zhiqiang Song, Liya Zhou, Jianzhong Zhang, Lihua He, Peng Bai, Yan Xue. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy. Digestive and Liver Disease 2016; 48(5): 506 doi: 10.1016/j.dld.2016.01.002
72
Myung Ho Jeong, Jun-Won Chung, Sang Jin Lee, Minsu Ha, Seok Hoo Jeong, Sunyoung Na, Byung Soo Na, Sung Keun Park, Yoon Jae Kim, Kwang An Kwon, Kwang Il Ko, Yunjeong Jo, Ki Baik Hahm, Hwoon-Yong Jung. Comparison of Rifabutin- and Levofloxacin-based Third-line Rescue Therapies forHelicobacter pylori. The Korean Journal of Gastroenterology 2012; 59(6): 401 doi: 10.4166/kjg.2012.59.6.401
73
Meng‐Shu Hsieh, Chung‐Jung Liu, Wen‐Hung Hsu, Chia‐Jung Li, Pei‐Yun Tsai, Huang‐Ming Hu, Hsiang‐Yao Shih, Chien‐Yu Lu, Fang‐Jung Yu, Fu‐Chen Kuo, Deng‐Chyang Wu, Chao‐Hung Kuo. Gastric juice‐based PCR assay: An alternative testing method to aid in the management of previously treated Helicobacter pylori infection. Helicobacter 2019; 24(2) doi: 10.1111/hel.12568
74
Amita Pathak, Victoria L. Blair, Richard L. Ferrero, Michael Mehring, Philip C. Andrews. Bismuth(iii) benzohydroxamates: powerful anti-bacterial activity against Helicobacter pylori and hydrolysis to a unique Bi34 oxido-cluster [Bi34O22(BHA)22(H-BHA)14(DMSO)6]. Chem. Commun. 2014; 50(96): 15232 doi: 10.1039/C4CC07329K
75
Tural Safarov, Bukre Kiran, Melahat Bagirova, Adil M Allahverdiyev, Emrah Sefik Abamor. An overview of nanotechnology-based treatment approaches against Helicobacter Pylori. Expert Review of Anti-infective Therapy 2019; 17(10): 829 doi: 10.1080/14787210.2019.1677464
76
Jyh-Ming Liou, Po-Yueh Chen, Yu-Ting Kuo, Ming-Shiang Wu. Toward population specific and personalized treatment of Helicobacter pylori infection. Journal of Biomedical Science 2018; 25(1) doi: 10.1186/s12929-018-0471-z
77
Hamza Olleik, Elias Baydoun, Josette Perrier, Akram Hijazi, Josette Raymond, Marine Manzoni, Lucas Dupuis, Ghislain Pauleau, Yvain Goudard, Bruno de La Villéon, Géraldine Goin, Philippe Sockeel, Muhammad Iqbal Choudhary, Eric Di Pasquale, Muhammad Nadeem-ul-Haque, Hunain Ali, Arif Iftikhar Khan, Farzana Shaheen, Marc Maresca. Temporin-SHa and Its Analogs as Potential Candidates for the Treatment of Helicobacter pylori. Biomolecules 2019; 9(10): 598 doi: 10.3390/biom9100598
78
G. Cammarota, M. Sanguinetti, A. Gallo, B. Posteraro. Review article: biofilm formation by Helicobacter pylori as a target for eradication of resistant infection. Alimentary Pharmacology & Therapeutics 2012; 36(3): 222 doi: 10.1111/j.1365-2036.2012.05165.x
79
Hyung Min Noh, Su Jin Hong, Jae Pil Han, Kyung Woo Park, Yun Nah Lee, Tae Hee Lee, Bong Min Ko, Joon Seong Lee, Moon Sung Lee. Eradication Rate by Duration of Third-line Rescue Therapy with Levofloxacin afterHelicobacter pyloriTreatment Failure in Clinical Practice. The Korean Journal of Gastroenterology 2016; 68(5): 260 doi: 10.4166/kjg.2016.68.5.260
80
Chengzhi Yuan, Chang Yu, Qifang Sun, Meng Xiong, Sainan Zhou, Meiyan Zeng, Houpan Song. Research on antibiotic resistance in Helicobacter pylori: a bibliometric analysis of the past decade. Frontiers in Microbiology 2023; 14 doi: 10.3389/fmicb.2023.1208157
81
Jun‐Won Chung, Gin Hyug Lee, Jin‐Yong Jeong, Sun Mi Lee, Ji Hoon Jung, Kee Don Choi, Ho June Song, Hwoon‐Yong Jung, Jin‐Ho Kim. Resistance of Helicobacter pylori strains to antibiotics in Korea with a focus on fluoroquinolone resistance. Journal of Gastroenterology and Hepatology 2012; 27(3): 493 doi: 10.1111/j.1440-1746.2011.06874.x
82
Alicia C Marin, Adrian G McNicholl, Javier P Gisbert. A review of rescue regimens after clarithromycin-containing triple therapy failure (forHelicobacter pylorieradication). Expert Opinion on Pharmacotherapy 2013; 14(7): 843 doi: 10.1517/14656566.2013.782286
83
A. Cuadrado-Lavin, J. R. Salcines-Caviedes, M. F. Carrascosa, T. Dierssen-Sotos, M. Cobo, M. R. Campos, B. Ayestaran, A. Fernandez-Pousa, E. Gonzalez-Colominas, S. Aresti-Zarate, M. Hernandez, E. L. Pascual. Levofloxacin versus clarithromycin in a 10 day triple therapy regimen for first-line Helicobacter pylori eradication: a single-blind randomized clinical trial. Journal of Antimicrobial Chemotherapy 2012; 67(9): 2254 doi: 10.1093/jac/dks209
84
Sotirios D Georgopoulos, Vasilios Papastergiou, Stylianos Karatapanis. Current options for the treatment ofHelicobacter pylori. Expert Opinion on Pharmacotherapy 2013; 14(2): 211 doi: 10.1517/14656566.2013.763926
85
Jyh‐Ming Liou, Ming‐Shiang Wu, Jaw‐Town Lin. Treatment of Helicobacter pylori infection: Where are we now?. Journal of Gastroenterology and Hepatology 2016; 31(12): 1918 doi: 10.1111/jgh.13418
Write to the Help Desk
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345